IOVA Price Prediction Next Week
Analysis and Insights
News and Fundamental Analysis:
Iovance Biotherapeutics (IOVA) has shown mixed performance recently. Chardan lowered its price target to $30 from $34 but maintained a Buy rating, citing Q4 results and the Amtagvi launch. While revenue met targets, reliance on Proleukin contributions indicates mixed revenue generation. Barclays maintained a Buy rating with a $22 target, while Stifel also issued a Buy rating, contrasting with Piper Sandler's Hold. The stock is currently trading at $4.24, significantly below its 52-week high of $18.24.
Recent news highlights Iovance as an overlooked growth stock with strong revenue growth projections. Q4 revenue was $73.7 million, with a 2025 forecast of $450-475 million, indicating strong demand for Amtagvi. Despite promising news, the stock is down over 90% from its 2021 high, potentially oversold.
Technical Analysis:
The stock is in an oversold condition with an RSI of 30.77, suggesting potential exhaustion of selling pressure. The MACD is slightly negative but showing signs of a bullish divergence. Fibonacci levels indicate support at $3.47 and resistance at $3.91.
Price Forecast:
Given the oversold RSI and potential bullish divergence in MACD, IOVA could see a short-term rebound. The stock is expected to test the Fibonacci resistance level of $3.91, with a potential upside to $4.20.
Buy/Sell Recommendation:
Buy at current levels, targeting $4.20. Stop-loss at $3.47.
IOVA Similar Chart Price Prediction
The price of IOVA is predicted to go up -18.59%, based on the high correlation periods with CHEF. The similarity of these two price pattern on the periods is 99.45%.
IOVA
CHEF
Down: -18.59%Similarity: 99.45%
IOVA Revenue Forecast
IOVA EPS Forecast
IOVA FAQs
What is IOVA revenue forecast for next quarter？
What is IOVA eps forecast for next quarter？
IOVA Analyst's Forecast
Asthika Goonewardene
Truist Securities
Strong Buy
2025-03-03
Price Target
$25 → $15
Upside
+271.29%
Truist lowered the firm's price target on Iovance Biotherapeutics to $15 from $25 and keeps a Buy rating on the shares after its Q4 results. The launch of Amtagvi is going well, but the guidance given early on was a tall order and has given bears ammunition, the analyst tells investors in a research note. With two quarters of slower growth - Q4 and expected Q1 - the ramp up needed for the rest of the year is almost unreasonably aggressive, Truist added.
Geulah Livshits
Chardan Capital
Strong Buy
2025-03-03
Price Target
$34 → $30
Upside
+642.57%
Michael Ulz
Baird
Buy
2025-02-28
Price Target
$24 → $20
Upside
+372.26%
